Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,755,555 shares of the biotechnology company’s stock after buying an additional 85,555 shares during the quarter. Ascendis Pharma A/S […]
Seven Eight Capital LP purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,636 shares of the biotechnology company’s stock, valued at approximately $2,347,000. A number of […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 3,460,000 shares, a decline of 6.5% from the April 30th total of 3,700,000 shares. Based on an average daily volume of 370,500 shares, […]
Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.
04.06.2024 - COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, .